ED worsened, testosterone levels decreased by some treatments of prostate enlargement

June 12, 2015, Boston University Medical Center

Men with benign prostate enlargement who used finasteride (also known as proscar and propecia) to treat their condition, experienced worsening erectile dysfunction (ED) that did not resolve with continued treatment. In addition, they experienced a reduction in their testosterone levels leading to hypogonadism (little to no production of sex hormones). However, men who used tamsulosin (flomax) experienced none of these adverse side effects.

The findings, currently available online in the journal Hormone Molecular Biology and Clinical Investigation, were led by researcher from Boston University School of Medicine (BUSM).

Considerable controversy exists regarding the severity and persistence of the adverse effects of 5α reductase inhibitors (5α-RIs) such as finasteride. Many investigators believe that the adverse effects on affects only a small proportion of treated patients and such are thought to resolve with continuing treatment.

The researchers studied 470 men who were treated with finasteride and 230 men who received the alpha blocker tamsulosin for their BPH. Both groups were followed for 45 months and were assessed for improvement of BPH symptoms. Prostate specific antigen and testosterone levels were also measured. The effects of the drugs on the quality of life were assessed by the Aging Male Symptom scale while the effects of the drugs on erectile function were assessed by the International Index of Erectile Function.

The researchers found that the men treated with finasteride experienced marked and significant gradual decrease in their erectile function and had significant and progressive decline in total while those on the tamsulosin therapy did not.

According to the researchers both of these drugs have been proven useful in treatment of lower urinary tract symptoms related to BPH. "However, 5α reductase inhibitors exert undesirable sexual side effects and, in some cases, these effects are persistent," explained corresponding author Abdulmaged M. Traish, MBA, PhD, professor of biochemistry and urology at BUSM. "Since sexual function is considered an integral part of overall health, it is important that physicians are aware of the of this class of drugs on human health in general and on sexual function in particular. Our study emphasized that the effect on erectile function is a serious concern and needs to be considered more carefully."

Explore further: Sexual dysfunction inadequately reported in hair loss drug trials

Related Stories

Sexual dysfunction inadequately reported in hair loss drug trials

April 1, 2015
Published reports of clinical trials provide insufficient information to adequately establish the safety of finasteride for treatment of hair loss in men, according to a new Northwestern Medicine study to be published April ...

Only high exercise levels tied to better erectile, sexual function

April 13, 2015
(HealthDay)—High weekly exercise levels are tied to better erectile/sexual function in men, whereas exercise at lower levels is not, according to a study published online March 20 in the Journal of Sexual Medicine.

Decreased sexual activity, desire may lead to decline in serum testosterone in older men

March 7, 2015
In older men, decreased sexual activity and desire, not erectile dysfunction, may cause serum testosterone to decline, a new study from Australia finds. The results will be presented Saturday March 7, at ENDO 2015, the annual ...

Finasteride, medication for male pattern hair loss, may also decrease drinking

June 13, 2013
Finasteride is a synthetic drug for the treatment of male pattern hair loss (MPHL) and an enlarged prostate. The side effects of finasteride for treatment of these two conditions can include increased rates of sexual dysfunction, ...

Recommended for you

Study identifies a key cellular mechanism that triggers pneumonia in humans

December 11, 2018
The relationship between influenza and pneumonia has long been observed by health workers. Its genetic and cellular mechanisms have now been investigated in depth by scientists in a study involving volunteers and conducted ...

Effect of oral alfacalcidol on clinical outcomes in patients without secondary hyperparathyroidism

December 11, 2018
Treatment with active vitamin D did not decrease cardiovascular events in kidney patients undergoing hemodialysis, according to a research group in Japan. They have reported their research results in the December 11 issue ...

Human antibody discovery could save lives from fungal killer

December 11, 2018
A new way to diagnose, treat and protect against stealth fungal infections that claim more than 1.5 million lives per year worldwide has been moved a step closer, according to research published in Nature Communications.

Dialysis patients at risk of progressive brain injury

December 10, 2018
Kidney dialysis can cause short-term 'cerebral stunning' and may be associated with progressive brain injury in those who receive the treatment for many years. For many patients with kidney failure awaiting a kidney transplant ...

Silicosis is on the rise, but is there a therapeutic target?

December 6, 2018
Researchers from the CNRS, the University of Orléans, and the company Artimmune, in collaboration with Turkish clinicians from Atatürk University, have identified a key mechanism of lung inflammation induced by silica exposure, ...

PET scans to optimize tuberculosis meningitis treatments and personalize care, study finds

December 6, 2018
Although relatively rare in the United States, and accounting for fewer than 5 percent of tuberculosis cases worldwide, TB of the brain—or tuberculosis meningitis (TBM)—is often deadly, always hard to treat, and a particular ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.